Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide
- 12 January 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 207 (5) , 1010-1019
Abstract
Purpose:Prostate cancer (PCa) patients treated with apalutamide frequently develop rash. We aim to characterize apalutamide-related dermatologic adverse events (dAE) and management.Materials and Me...Keywords
This publication has 21 references indexed in Scilit:
- Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and CabazitaxelClinical Genitourinary Cancer, 2015
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate ThemEuropean Urology, 2015
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2015
- Evaluation of histopathological findings at the injection site following degarelix administrationSupportive Care in Cancer, 2014
- A case of foreign body granuloma induced by subcutaneous injection of leuprorelin acetate─clinical analysis for 335 cases in our hospital─.2014
- ARN-509: A Novel Antiandrogen for Prostate Cancer TreatmentCancer Research, 2012
- Characterising the castration-resistant prostate cancer population: a systematic reviewInternational Journal Of Clinical Practice, 2011
- Drug-induced cutaneous pathologyJournal of Clinical Pathology, 2009
- Delayed drug hypersensitivity reactions – new conceptsClinical & Experimental Allergy, 2007
- Androgen Deprivation Therapy for Prostate CancerJAMA, 2005